Notably, a recent innovative strategy in oncology therapy—blocking the pathway linking metabolic reprogramming and proteomic remodeling in tumor cells by inhibiting aminoacyl-tRNA synthetase 1 (AARS1) (Li H. et al., 2024; Zong et al., 2024; Li et al., 2025)—offers a new approach for treating IDD. The gene discussed is AARS1; the disease is intervertebral disk degenerative disorder.